Carcinoma, Squamous, Head and Neck Neoplasms
Conditions
Brief summary
Patients undergoing primary radiochhemotherapy for locally advanced head and neck squamous cell carcinomas are included in this study. In addition to standard of care treatment patients will undergo addiational blood draws and MR imaging studies. Circulating cell free tumor DNA will be analysed in the blood samples. BIological data, imaging data and clinical data (such as patient and tumor characteristics, oncologic outcome, side effects) will be analysed in a biomathematical modelling approach.
Interventions
OTHERBlood draw, MRI
Blood draw, MRI
Sponsors
Franziska Eckert
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Squamous cell carcinoma head and neck * Planned primary platinum based radiochemotherapy * ECOG 0-2
Exclusion criteria
* Palliative therapy intent * Not MR eligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percentage of patients with 50% decrease in ctDNA | 7 weeks after start of radiotherapy |
Secondary
| Measure | Time frame |
|---|---|
| Completion of all planned MR imagings and blood tests | through study completion, an average of 7 weeks |
| Decrease of tumor volume | 7 weeks after start of radiotherapy |
Contacts
Primary ContactFranziska Eckert, M.D.
Outcome results
None listed